Skip to main content

Articles

Page 5 of 18

  1. Alzheimer’s disease (AD) is responsible for 60–70% of all cases of dementia. On the other hand, the tap water consumed by hundreds of millions of people has been fluoridated to prevent tooth decay. However, li...

    Authors: Kun Cao, Jie Xiang, Yang-Ting Dong, Yi Xu, Yi Li, Hui Song, Xiao-Xiao Zeng, Long-Yan Ran, Wei Hong and Zhi-Zhong Guan

    Citation: Alzheimer's Research & Therapy 2019 11:35

    Content type: Research

    Published on:

  2. The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairmen...

    Authors: Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg and Piotr Lewczuk

    Citation: Alzheimer's Research & Therapy 2019 11:34

    Content type: Review

    Published on:

  3. Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage take...

    Authors: Ingrid S. van Maurik, Rosalinde E. R. Slot, Sander C. J. Verfaillie, Marissa D. Zwan, Femke H. Bouwman, Niels D. Prins, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Mike P. Wattjes, Jose Luis Molinuevo, Lorena Rami, Steffen Wolfsgruber, Oliver Peters, Frank Jessen, Johannes Berkhof…

    Citation: Alzheimer's Research & Therapy 2019 11:33

    Content type: Research

    Published on:

  4. The leading causes of death among the elderly with cognitive impairment are unknown. This study aims to estimate the suicide and accidental death rates on the basis of a clinical case registry of patients diag...

    Authors: Ji Hyun An, Kyung Eun Lee, Hong Jin Jeon, Sang Joon Son, Sung Yoon Kim and Jin Pyo Hong

    Citation: Alzheimer's Research & Therapy 2019 11:32

    Content type: Research

    Published on:

  5. Dementia is prevalent in the end-stage renal disease (ESRD) population. However, it is still not clarified whether ESRD is one of the etiology of dementia or its attributable effect on the cumulative risk of d...

    Authors: Yi-Ting Kuo, Chung-Yi Li, Junne-Ming Sung, Chiung-Chih Chang, Jung-Der Wang, Chien-Yao Sun, Jia-Ling Wu and Yu-Tzu Chang

    Citation: Alzheimer's Research & Therapy 2019 11:31

    Content type: Research

    Published on:

  6. The phenocopy syndrome of behavioral variant of frontotemporal dementia (phFTD) refers to patients presenting with neuropsychiatric symptoms mimicking the behavioral variant frontotemporal dementia (bvFTD), bu...

    Authors: Elizabeth Sakamoto Valente, Paulo Caramelli, Leandro Boson Gambogi, Luciano Inácio Mariano, Henrique Cerqueira Guimarães, Antônio Lúcio Teixeira and Leonardo Cruz de Souza

    Citation: Alzheimer's Research & Therapy 2019 11:30

    Content type: Review

    Published on:

  7. Alzheimer’s disease (AD) is the sixth leading cause of death, with an average survival estimated between 5 and 10 years after diagnosis. Despite recent advances in diagnostic criteria of AD, few studies have u...

    Authors: Adla Boumenir, Emmanuel Cognat, Severine Sabia, Claire Hourregue, Matthieu Lilamand, Aline Dugravot, Elodie Bouaziz-Amar, Jean-Louis Laplanche, Jacques Hugon, Archana Singh-Manoux, Claire Paquet and Julien Dumurgier

    Citation: Alzheimer's Research & Therapy 2019 11:29

    Content type: Research

    Published on:

  8. Synaptic damage precedes neuron death in Alzheimer’s disease (AD). Neurexins, NRXN1, NRXN2, and NRXN3, are presynaptic adhesion molecules that specify neuron synapses and regulate neurotransmitter release. Neurex...

    Authors: Akitoyo Hishimoto, Olga Pletnikova, Doyle Lu Lang, Juan C. Troncoso, Josephine M. Egan and Qing-Rong Liu

    Citation: Alzheimer's Research & Therapy 2019 11:28

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2019 11:39

  9. The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making fo...

    Authors: Gemma Salvadó, José Luis Molinuevo, Anna Brugulat-Serrat, Carles Falcon, Oriol Grau-Rivera, Marc Suárez-Calvet, Javier Pavia, Aida Niñerola-Baizán, Andrés Perissinotti, Francisco Lomeña, Carolina Minguillon, Karine Fauria, Henrik Zetterberg, Kaj Blennow and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2019 11:27

    Content type: Research

    Published on:

  10. Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer’s disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding r...

    Authors: Carla M. Startin, Nicholas J. Ashton, Sarah Hamburg, Rosalyn Hithersay, Frances K. Wiseman, Kin Y. Mok, John Hardy, Alberto Lleó, Simon Lovestone, Lucilla Parnetti, Henrik Zetterberg, Abdul Hye and André Strydom

    Citation: Alzheimer's Research & Therapy 2019 11:26

    Content type: Research

    Published on:

  11. In clinical practice, it is often difficult to predict which patients with cognitive complaints or impairment will progress or remain stable. We assessed the impact of using a clinical decision support system,...

    Authors: Marie Bruun, Kristian S. Frederiksen, Hanneke F. M. Rhodius-Meester, Marta Baroni, Le Gjerum, Juha Koikkalainen, Timo Urhemaa, Antti Tolonen, Mark van Gils, Daniel Rueckert, Nadia Dyremose, Birgitte B. Andersen, Afina W. Lemstra, Merja Hallikainen, Sudhir Kurl, Sanna-Kaisa Herukka…

    Citation: Alzheimer's Research & Therapy 2019 11:25

    Content type: Research

    Published on:

  12. Although previous studies have revealed many factors related to mild cognitive impairment (MCI) reversion, information about reversible factors related MCI reversion is limited, impeding the development of int...

    Authors: Hiroyuki Shimada, Takehiko Doi, Sangyoon Lee and Hyuma Makizako

    Citation: Alzheimer's Research & Therapy 2019 11:24

    Content type: Research

    Published on:

  13. The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient acces...

    Authors: Bethany Peterson, Melissa Armstrong, Douglas Galasko, James E. Galvin, Jennifer Goldman, David Irwin, Henry Paulson, Daniel Kaufer, James Leverenz, Angela Lunde, Ian G. McKeith, Andrew Siderowf, Angela Taylor, Katherine Amodeo, Matt Barrett, Kimiko Domoto-Reilly…

    Citation: Alzheimer's Research & Therapy 2019 11:23

    Content type: Meeting report

    Published on:

  14. A primary goal of research in cognitive impairment and dementia is to understand how some individuals retain sufficient cognitive function for a fulfilling life while many others are robbed of their independen...

    Authors: Thomas J. Montine, Brenna A. Cholerton, Maria M. Corrada, Steven D. Edland, Margaret E. Flanagan, Laura S. Hemmy, Claudia H. Kawas and Lon R. White

    Citation: Alzheimer's Research & Therapy 2019 11:22

    Content type: Commentary

    Published on:

  15. The objective of this systematic review was (1) to give an overview of the available short screening instruments for the early detection of Alzheimer’s disease (AD) and (2) to review the psychometric propertie...

    Authors: Ellen Elisa De Roeck, Peter Paul De Deyn, Eva Dierckx and Sebastiaan Engelborghs

    Citation: Alzheimer's Research & Therapy 2019 11:21

    Content type: Review

    Published on:

  16. [18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodeg...

    Authors: Silvia Paola Caminiti, Arianna Sala, Leonardo Iaccarino, Luca Beretta, Andrea Pilotto, Luigi Gianolli, Sandro Iannaccone, Giuseppe Magnani, Alessandro Padovani, Luigi Ferini-Strambi and Daniela Perani

    Citation: Alzheimer's Research & Therapy 2019 11:20

    Content type: Research

    Published on:

  17. To investigate how serum neurofilament light (NfL) concentration changes through the course of disease in familial Alzheimer’s disease (FAD) and to assess when NfL concentration first increases.

    Authors: Philip S. J. Weston, Teresa Poole, Antoinette O’Connor, Amanda Heslegrave, Natalie S. Ryan, Yuying Liang, Ronald Druyeh, Simon Mead, Kaj Blennow, Jonathan M. Schott, Chris Frost, Henrik Zetterberg and Nick C. Fox

    Citation: Alzheimer's Research & Therapy 2019 11:19

    Content type: Research

    Published on:

  18. There are currently no approved treatments for the prodromal stage of Alzheimer’s disease (AD). Approved symptomatic treatments for mild-to-moderate AD include acetylcholinesterase inhibitors and memantine, bu...

    Authors: Lutz Frölich, Glen Wunderlich, Claus Thamer, Michael Roehrle, Miguel Garcia Jr and Bruno Dubois

    Citation: Alzheimer's Research & Therapy 2019 11:18

    Content type: Research

    Published on:

  19. Autosomal dominant Alzheimer’s disease (ADAD) is distinguished from late-onset AD by early striatal amyloid-β deposition. To determine whether striatal Pittsburgh compound B (PiB)-PET measurements of amyloid-β...

    Authors: Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Daniel J. Norton, Edmarie Guzman-Velez, Ana Baena, Enmanuelle Pardilla-Delgado, Aaron P. Schultz, Jennifer Gatchel, David Jin, Kewei Chen, Eric M. Reiman, Keith A. Johnson and Yakeel T. Quiroz

    Citation: Alzheimer's Research & Therapy 2019 11:17

    Content type: Research

    Published on:

  20. Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer’s disease (LOAD). Amongst these, a polymorphism in phospholipase C-...

    Authors: Lorenza Magno, Christian B. Lessard, Marta Martins, Verena Lang, Pedro Cruz, Yasmine Asi, Matilda Katan, Jamie Bilsland, Tammaryn Lashley, Paramita Chakrabarty, Todd E. Golde and Paul J. Whiting

    Citation: Alzheimer's Research & Therapy 2019 11:16

    Content type: Research

    Published on:

  21. Current methods of amyloid PET interpretation based on the binary classification of global amyloid signal fail to identify early phases of amyloid deposition. A recent analysis of 18F-florbetapir PET data from...

    Authors: Fatemah A. Sakr, Michel J. Grothe, Enrica Cavedo, Irina Jelistratova, Marie-Odile Habert, Martin Dyrba, Gabriel Gonzalez-Escamilla, Hugo Bertin, Maxime Locatelli, Stephane Lehericy, Stefan Teipel, Bruno Dubois and Harald Hampel

    Citation: Alzheimer's Research & Therapy 2019 11:15

    Content type: Research

    Published on:

  22. A decline in instrumental activities of daily living (IADL) correlates with the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia and has been associated with frontal and pa...

    Authors: Omar A. Halawa, Jennifer R. Gatchel, Rebecca E. Amariglio, Dorene M. Rentz, Reisa A. Sperling, Keith A. Johnson and Gad A. Marshall

    Citation: Alzheimer's Research & Therapy 2019 11:14

    Content type: Research

    Published on:

  23. The tau positron emission tomography (PET) ligand 18F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dem...

    Authors: Richard M. Tsai, Alexandre Bejanin, Orit Lesman-Segev, Renaud LaJoie, Adrienne Visani, Viktoriya Bourakova, James P. O’Neil, Mustafa Janabi, Suzanne Baker, Suzee E. Lee, David C. Perry, Lynn Bajorek, Anna Karydas, Salvatore Spina, Lea T. Grinberg, William W. Seeley…

    Citation: Alzheimer's Research & Therapy 2019 11:13

    Content type: Research

    Published on:

  24. White matter hyperintensities (WMH) of presumed vascular origin have been associated with an increased risk of Alzheimer’s disease (AD). This study aims to describe the patterns of WMH associated with dementia...

    Authors: Gemma Salvadó, Anna Brugulat-Serrat, Carole H. Sudre, Oriol Grau-Rivera, Marc Suárez-Calvet, Carles Falcon, Karine Fauria, M. Jorge Cardoso, Frederik Barkhof, José Luis Molinuevo and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2019 11:12

    Content type: Research

    Published on:

  25. We developed multifactorial models for predicting incident dementia and brain pathology in the oldest old using the Vantaa 85+ cohort.

    Authors: Anette Hall, Timo Pekkala, Tuomo Polvikoski, Mark van Gils, Miia Kivipelto, Jyrki Lötjönen, Jussi Mattila, Mia Kero, Liisa Myllykangas, Mira Mäkelä, Minna Oinas, Anders Paetau, Hilkka Soininen, Maarit Tanskanen and Alina Solomon

    Citation: Alzheimer's Research & Therapy 2019 11:11

    Content type: Research

    Published on:

  26. Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer’s disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few...

    Authors: Yeo Jin Kim, Seong-Kyoung Cho, Hee Jin Kim, Jin San Lee, Juyoun Lee, Young Kyoung Jang, Jacob W. Vogel, Duk L. Na, Changsoo Kim and Sang Won Seo

    Citation: Alzheimer's Research & Therapy 2019 11:10

    Content type: Research

    Published on:

  27. Complex visual hallucinations are common in Lewy body dementia (LBD) and can cause significant patient and caregiver distress. Current treatments are primarily pharmacological in nature and have limited effica...

    Authors: Greg J. Elder, Sean J. Colloby, Michael J. Firbank, Ian G. McKeith and John-Paul Taylor

    Citation: Alzheimer's Research & Therapy 2019 11:9

    Content type: Research

    Published on:

  28. Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future...

    Authors: Steffen Wolfsgruber, José Luis Molinuevo, Michael Wagner, Charlotte E. Teunissen, Lorena Rami, Nina Coll-Padrós, Femke H. Bouwman, Rosalinde E. R. Slot, Linda M. P. Wesselman, Oliver Peters, Katja Luther, Katharina Buerger, Josef Priller, Christoph Laske, Stefan Teipel, Annika Spottke…

    Citation: Alzheimer's Research & Therapy 2019 11:8

    Content type: Research

    Published on:

  29. Alzheimer’s disease (AD) pathology begins several years before the clinical onset. The long preclinical phase is composed of three stages according to the 2011National Institute on Aging and Alzheimer’s Associ...

    Authors: Lucilla Parnetti, Elena Chipi, Nicola Salvadori, Katia D’Andrea and Paolo Eusebi

    Citation: Alzheimer's Research & Therapy 2019 11:7

    Content type: Research

    Published on:

  30. The annual incidence of traumatic brain injury (TBI) in the United States is over 2.5 million, with approximately 3–5 million people living with chronic sequelae. Compared with moderate-severe TBI, the long-te...

    Authors: Wai Hang Cheng, Kris M. Martens, Asma Bashir, Honor Cheung, Sophie Stukas, Ebrima Gibbs, Dhananjay R. Namjoshi, Emily B. Button, Anna Wilkinson, Carlos J. Barron, Neil R. Cashman, Peter A. Cripton and Cheryl L. Wellington

    Citation: Alzheimer's Research & Therapy 2019 11:6

    Content type: Research

    Published on:

  31. Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and the sixth leading cause of death in the United States. AD is mainly considered a complex disorder with polygenic inheritance. De...

    Authors: Alireza Nazarian, Anatoliy I. Yashin and Alexander M. Kulminski

    Citation: Alzheimer's Research & Therapy 2019 11:5

    Content type: Research

    Published on:

  32. Impairment in instrumental activities of daily living (IADL) may occur in the earliest stages of mild cognitive impairment (MCI). However, there are few reliable measures of IADL in MCI or that have a sufficie...

    Authors: Gad A. Marshall, Sarah L. Aghjayan, Maria Dekhtyar, Joseph J. Locascio, Kamal Jethwani, Rebecca E. Amariglio, Sara J. Czaja, David A. Loewenstein, Keith A. Johnson, Reisa A. Sperling and Dorene M. Rentz

    Citation: Alzheimer's Research & Therapy 2019 11:4

    Content type: Research

    Published on:

  33. Exercise is often proposed as a non-pharmacological intervention to delay cognitive decline in people with dementia, but evidence remains inconclusive. Previous studies suggest that combining physical exercise...

    Authors: Esther G. A. Karssemeijer, Justine A. Aaronson, Willem J. R. Bossers, Rogier Donders, Marcel G. M. Olde Rikkert and Roy P. C. Kessels

    Citation: Alzheimer's Research & Therapy 2019 11:3

    Content type: Research

    Published on:

  34. The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from neur...

    Authors: Inês Baldeiras, Isabel Santana, Maria João Leitão, Daniela Vieira, Diana Duro, Barbara Mroczko, Johannes Kornhuber and Piotr Lewczuk

    Citation: Alzheimer's Research & Therapy 2019 11:2

    Content type: Research

    Published on:

  35. Alcohol use has been identified as a risk factor for dementia and cognitive decline. However, some patterns of drinking have been associated with beneficial effects.

    Authors: Jürgen Rehm, Omer S. M. Hasan, Sandra E. Black, Kevin D. Shield and Michaël Schwarzinger

    Citation: Alzheimer's Research & Therapy 2019 11:1

    Content type: Review

    Published on:

  36. Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. ...

    Authors: Kai-Xin Dou, Meng-Shan Tan, Chen-Chen Tan, Xi-Peng Cao, Xiao-He Hou, Qi-Hao Guo, Lan Tan, Vincent Mok and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2018 10:126

    Content type: Research

    Published on:

  37. The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice.

    Authors: Joshua D. Grill, Chelsea G. Cox, Kristin Harkins and Jason Karlawish

    Citation: Alzheimer's Research & Therapy 2018 10:125

    Content type: Research

    Published on:

    The Letter to this article has been published in Alzheimer's Research & Therapy 2019 11:52

  38. Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s diseas...

    Authors: Nicholas M. Vogt, Kymberleigh A. Romano, Burcu F. Darst, Corinne D. Engelman, Sterling C. Johnson, Cynthia M. Carlsson, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin and Federico E. Rey

    Citation: Alzheimer's Research & Therapy 2018 10:124

    Content type: Research

    Published on:

  39. Subjective cognitive decline (SCD) consists of self-perceived decline in cognition over time. The occurrence of specific additional features in SCD (so-called SCDplus) confers a higher risk of future cognitive...

    Authors: Gonzalo Sánchez-Benavides, Oriol Grau-Rivera, Marc Suárez-Calvet, Carolina Minguillon, Raffaele Cacciaglia, Nina Gramunt, Carles Falcon, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2018 10:123

    Content type: Research

    Published on:

  41. The quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may int...

    Authors: Hedieh Shahpasand-Kroner, Hans-W. Klafki, Chris Bauer, Johannes Schuchhardt, Melanie Hüttenrauch, Martina Stazi, Caroline Bouter, Oliver Wirths, Jonathan Vogelgsang and Jens Wiltfang

    Citation: Alzheimer's Research & Therapy 2018 10:121

    Content type: Research

    Published on:

  42. Upon publication of this article [1], it was brought to our attention that one of the 303 participants in the normative study should have been deleted from the database.

    Authors: Morris Freedman, Larry Leach, M. Carmela Tartaglia, Kathryn A. Stokes, Yael Goldberg, Robyn Spring, Nima Nourhaghighi, Tom Gee, Stephen C. Strother, Mohammad O. Alhaj, Michael Borrie, Sultan Darvesh, Alita Fernandez, Corinne E. Fischer, Jennifer Fogarty, Barry D. Greenberg…

    Citation: Alzheimer's Research & Therapy 2018 10:120

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2018 10:65

  43. Peripheral biomarkers that identify individuals at risk of developing Alzheimer’s disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disea...

    Authors: Itziar de Rojas, J. Romero, O. Rodríguez-Gomez, P. Pesini, A. Sanabria, A. Pérez-Cordon, C. Abdelnour, I. Hernández, M. Rosende-Roca, A. Mauleón, L. Vargas, M. Alegret, A. Espinosa, G. Ortega, S. Gil, M. Guitart…

    Citation: Alzheimer's Research & Therapy 2018 10:119

    Content type: Research

    Published on:

  44. Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute con...

    Authors: Stephen P. Schauer, William R. Mylott Jr, Moucun Yuan, Rand G. Jenkins, W. Rodney Mathews, Lee A. Honigberg and Kristin R. Wildsmith

    Citation: Alzheimer's Research & Therapy 2018 10:118

    Content type: Research

    Published on:

  45. Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targe...

    Authors: Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Patrick Benoit, Pascal Barneoud, Véronique Taupin, Philippe Bertrand, Philippe Dugay, Béatrice Cameron, Yi Shi, Souad Naimi, Marc Duchesne, Marie Gagnaire, Tim Weeden…

    Citation: Alzheimer's Research & Therapy 2018 10:117

    Content type: Research

    Published on:

  46. Globalization of clinical trials has important consequences for trial planning and interpretation. This study investigated heterogeneity in patient characteristics and outcomes among world regions in the globa...

    Authors: Jeffrey L. Cummings, Alireza Atri, Clive Ballard, Neli Boneva, Lutz Frölich, José Luis Molinuevo, Lars Lau Raket and Pierre N. Tariot

    Citation: Alzheimer's Research & Therapy 2018 10:116

    Content type: Research

    Published on:

  47. Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of AD. Using a triple-tr...

    Authors: Roger N. Rosenberg, Min Fu and Doris Lambracht-Washington

    Citation: Alzheimer's Research & Therapy 2018 10:115

    Content type: Research

    Published on:

  48. Low haemoglobin is highly prevalent among the elderly and has been associated with dementia. However, the mechanisms underlying this association with cognitive dysfunction, either through cerebrovascular disea...

    Authors: Bryce Tan, Narayanaswamy Venketasubramanian, Henri Vrooman, Ching-Yu Cheng, Tien Yin Wong, Christopher Chen and Saima Hilal

    Citation: Alzheimer's Research & Therapy 2018 10:114

    Content type: Research

    Published on:

  49. Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clin...

    Authors: Raquel Sánchez-Valle, Amanda Heslegrave, Martha S. Foiani, Beatriz Bosch, Anna Antonell, Mircea Balasa, Albert Lladó, Henrik Zetterberg and Nick C. Fox

    Citation: Alzheimer's Research & Therapy 2018 10:113

    Content type: Research

    Published on:

  50. In Alzheimer’s disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-d...

    Authors: Mara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N. M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, Derek Hill, Michael C. Irizarry, Adriaan A. Lammertsma, José Luis Molinuevo, Craig Ritchie, Philip Scheltens, Mark E. Schmidt…

    Citation: Alzheimer's Research & Therapy 2018 10:112

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193